Genmab and Merus had announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab, which is in Phase 3...

Roche has signed a definitive merger agreement for the acquisition of clinical-stage biopharmaceutical company 89bio, for a total equity value of around $2.4bn. Under the deal, Roche will initiate a tender offer to purchase all outstanding shares of 89bio common stock at $14.50 per...

Merck, a leading science and technology company, had announced that it has closed the acquisition of SpringWorks Therapeutics, for an enterprise value of $3.4 billion, following regulatory clearances and the fulfillment of other customary closing conditions. The definitive...